lenvatinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 4942 417716-92-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • E-7080
  • E 7080
  • lenvatinib
  • lenvima
  • ER-203492-00
  • E7080
  • lenvatinib mesylate
  • lenvatinib mesilate
a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4)
  • Molecular weight: 426.86
  • Formula: C21H19ClN4O4
  • CLOGP: 3.05
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 3
  • TPSA: 115.57
  • ALOGS: -4.84
  • ROTB: 6

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
18 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
May 28, 2015 EMA Eisai Europe Ltd
Feb. 13, 2015 FDA EISAI INC
March 26, 2015 PMDA Eisai Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypertension 1785.27 26.03 1091 18606 278212 63191113
Malignant neoplasm progression 1747.41 26.03 727 18970 81394 63387931
Proteinuria 1114.39 26.03 357 19340 18788 63450537
Hypothyroidism 1049.84 26.03 420 19277 42212 63427113
Palmar-plantar erythrodysaesthesia syndrome 879.81 26.03 313 19384 22702 63446623
Platelet count decreased 651.33 26.03 420 19277 115702 63353623
Decreased appetite 600.78 26.03 546 19151 250506 63218819
Immune-mediated hypothyroidism 313.87 26.03 58 19639 250 63469075
Diarrhoea 274.06 26.03 649 19048 714717 62754608
Hepatic encephalopathy 225.63 26.03 96 19601 11186 63458139
Malaise 210.45 26.03 423 19274 415531 63053794
Dysphonia 203.68 26.03 146 19551 47468 63421857
Thyroiditis 189.56 26.03 57 19640 2409 63466916
Hepatic function abnormal 187.24 26.03 126 19571 37016 63432309
Gastrointestinal perforation 186.07 26.03 61 19636 3430 63465895
Cholecystitis 179.32 26.03 90 19607 15287 63454038
Hyperthyroidism 177.36 26.03 88 19609 14585 63454740
Drug ineffective 177.04 26.03 53 19644 1044712 62424613
Blood pressure increased 167.77 26.03 228 19469 161834 63307491
Blood thyroid stimulating hormone increased 163.26 26.03 67 19630 7127 63462198
Pyrexia 160.16 26.03 409 19288 470069 62999256
Renal impairment 151.91 26.03 161 19536 88194 63381131
Stomatitis 125.41 26.03 183 19514 138542 63330783
Cardiac failure 121.60 26.03 144 19553 88998 63380327
Adrenal insufficiency 118.09 26.03 72 19625 17843 63451482
Interstitial lung disease 106.68 26.03 113 19584 61795 63407530
Tumour haemorrhage 105.40 26.03 33 19664 1598 63467727
Pneumothorax 101.19 26.03 63 19634 16198 63453127
Myocarditis 96.19 26.03 52 19645 10273 63459052
Fistula 95.87 26.03 52 19645 10341 63458984
Condition aggravated 89.88 26.03 10 19687 402207 63067118
Thrombocytopenia 88.56 26.03 164 19533 150993 63318332
Posterior reversible encephalopathy syndrome 82.98 26.03 57 19640 17288 63452037
Ascites 80.39 26.03 80 19617 40648 63428677
Colitis 79.05 26.03 86 19611 48442 63420883
Tracheal fistula 74.52 26.03 13 19684 37 63469288
Nephrotic syndrome 72.01 26.03 35 19662 5541 63463784
Drug hypersensitivity 71.24 26.03 7 19690 310680 63158645
Pain 67.01 26.03 79 19618 740549 62728776
Immune-mediated myocarditis 66.45 26.03 16 19681 284 63469041
Swelling 66.41 26.03 5 19692 275373 63193952
Hypersensitivity 66.04 26.03 7 19690 292678 63176647
Immune-mediated hepatic disorder 62.51 26.03 17 19680 498 63468827
Weight increased 62.14 26.03 5 19692 260787 63208538
Cholecystitis acute 61.72 26.03 36 19661 8224 63461101
Thyroid disorder 61.37 26.03 45 19652 15117 63454208
Protein urine present 60.31 26.03 32 19665 6088 63463237
Rheumatoid arthritis 60.10 26.03 5 19692 253814 63215511
Fatigue 58.07 26.03 471 19226 887557 62581768
Intestinal perforation 56.48 26.03 39 19658 11924 63457401
Adrenocorticotropic hormone deficiency 56.36 26.03 15 19682 404 63468921
Immune-mediated enterocolitis 55.98 26.03 22 19675 2089 63467236
Arthropathy 54.57 26.03 5 19692 234787 63234538
Cerebral haemorrhage 54.52 26.03 57 19640 30672 63438653
Off label use 53.73 26.03 79 19618 674383 62794942
Alopecia 53.48 26.03 19 19678 337517 63131808
Toxicity to various agents 53.07 26.03 7 19690 247243 63222082
Immune-mediated hyperthyroidism 52.98 26.03 11 19686 95 63469230
Dehydration 52.81 26.03 145 19552 173209 63296116
Joint swelling 52.67 26.03 18 19679 327648 63141677
Hypertensive crisis 52.21 26.03 41 19656 15245 63454080
Infusion related reaction 50.26 26.03 8 19689 245513 63223812
Immune-mediated hepatitis 49.85 26.03 18 19679 1353 63467972
Large intestine perforation 48.11 26.03 31 19666 8451 63460874
Small intestinal perforation 48.09 26.03 18 19679 1497 63467828
Oesophageal fistula 47.67 26.03 11 19686 161 63469164
Sinusitis 47.27 26.03 7 19690 226646 63242679
Product dose omission issue 45.00 26.03 9 19688 234304 63235021
Hyponatraemia 44.95 26.03 104 19593 111796 63357529
Drug intolerance 44.58 26.03 20 19677 308641 63160684
Oral pain 43.94 26.03 49 19648 28345 63440980
Weight decreased 43.88 26.03 186 19511 276612 63192713
Enterocolitis 42.81 26.03 28 19669 7830 63461495
Fall 42.05 26.03 36 19661 392298 63077027
Mucosal inflammation 39.58 26.03 60 19637 46868 63422457
Nasopharyngitis 39.09 26.03 15 19682 254242 63215083
Arterial haemorrhage 38.98 26.03 16 19681 1701 63467624
Vomiting 38.66 26.03 301 19396 559316 62910009
Hypopituitarism 37.76 26.03 14 19683 1134 63468191
Discomfort 37.73 26.03 4 19693 167370 63301955
Female genital tract fistula 36.52 26.03 25 19672 7534 63461791
Cerebral infarction 34.87 26.03 40 19657 23853 63445472
Depression 34.81 26.03 9 19688 196483 63272842
Immune-mediated encephalitis 34.46 26.03 9 19688 225 63469100
Cholangitis 33.22 26.03 21 19676 5540 63463785
Eastern Cooperative Oncology Group performance status worsened 33.01 26.03 13 19684 1241 63468084
Tumour lysis syndrome 32.63 26.03 25 19672 8965 63460360
Tracheal haemorrhage 32.42 26.03 8 19689 158 63469167
Immune-mediated dermatitis 31.43 26.03 8 19689 180 63469145
Pruritus 31.04 26.03 40 19657 361413 63107912
Nausea 29.28 26.03 398 19299 854073 62615252
Taste disorder 29.12 26.03 28 19669 13634 63455691
Peritonitis 28.97 26.03 31 19666 17123 63452202
Asthma 28.87 26.03 3 19694 127558 63341767
Myelosuppression 28.55 26.03 36 19661 23667 63445658
Epistaxis 28.54 26.03 67 19630 72658 63396667
Musculoskeletal stiffness 28.18 26.03 11 19686 184607 63284718
Bronchitis 28.12 26.03 3 19694 124932 63344393
Dizziness 28.07 26.03 57 19640 429868 63039457
Abdominal pain 27.99 26.03 171 19526 293285 63176040
Neutrophil count decreased 27.85 26.03 57 19640 56349 63412976
Pleural effusion 26.41 26.03 76 19621 93134 63376191
Amylase increased 26.05 26.03 19 19678 6326 63462999

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 879.50 20.87 554 17649 87492 34851236
Decreased appetite 851.15 20.87 696 17507 165696 34773032
Hepatic encephalopathy 799.81 20.87 297 17906 14388 34924340
Proteinuria 765.52 20.87 307 17896 18335 34920393
Hypertension 726.72 20.87 585 17618 135858 34802870
Palmar-plantar erythrodysaesthesia syndrome 683.96 20.87 275 17928 16520 34922208
Diarrhoea 409.75 20.87 726 17477 389186 34549542
Hypothyroidism 391.15 20.87 199 18004 20703 34918025
Tumour haemorrhage 277.74 20.87 90 18113 2872 34935856
Dysphonia 190.41 20.87 130 18073 23253 34915475
Liver carcinoma ruptured 176.23 20.87 36 18167 155 34938573
Malaise 170.65 20.87 328 17875 185497 34753231
Blood pressure increased 146.97 20.87 204 17999 87898 34850830
Fatigue 145.26 20.87 472 17731 370181 34568547
Oesophageal varices haemorrhage 136.46 20.87 54 18149 3092 34935636
Hepatic function abnormal 130.33 20.87 137 18066 44226 34894502
Ascites 124.82 20.87 137 18066 46434 34892294
Stomatitis 117.30 20.87 127 18076 42387 34896341
Cholecystitis 112.91 20.87 70 18133 10618 34928110
Drug ineffective 106.22 20.87 53 18150 456698 34482030
Hepatic failure 94.96 20.87 103 18100 34428 34904300
Cholangitis 94.56 20.87 58 18145 8631 34930097
Ammonia increased 91.64 20.87 45 18158 4324 34934404
Adrenal insufficiency 82.22 20.87 64 18139 13983 34924745
Pneumothorax 80.60 20.87 72 18131 19020 34919708
Blood bilirubin increased 78.14 20.87 98 18105 38198 34900530
Blood thyroid stimulating hormone increased 77.99 20.87 40 18163 4215 34934513
Platelet count decreased 71.46 20.87 178 18025 119539 34819189
Dehydration 71.13 20.87 187 18016 129782 34808946
Interstitial lung disease 70.69 20.87 124 18079 65158 34873570
Drug interaction 70.02 20.87 16 18187 225930 34712798
Condition aggravated 69.63 20.87 9 18194 192187 34746541
Toxicity to various agents 66.62 20.87 12 18191 200350 34738378
Oral pain 64.82 20.87 50 18153 10777 34927951
Tumour rupture 60.44 20.87 16 18187 245 34938483
Tracheal fistula 55.23 20.87 13 18190 119 34938609
Off label use 52.77 20.87 86 18117 419438 34519290
Cholecystitis acute 50.47 20.87 35 18168 6404 34932324
Portal vein thrombosis 48.27 20.87 28 18175 3760 34934968
Thyroiditis 45.60 20.87 23 18180 2339 34936389
Gastrointestinal perforation 45.15 20.87 27 18176 3836 34934892
Immune-mediated hepatitis 44.03 20.87 22 18181 2193 34936535
Epistaxis 43.90 20.87 95 18108 58156 34880572
Weight decreased 43.24 20.87 194 18009 176107 34762621
Tracheo-oesophageal fistula 42.79 20.87 14 18189 460 34938268
Nephrotic syndrome 42.13 20.87 33 18170 7270 34931458
Completed suicide 39.68 20.87 3 18200 98165 34840563
Hyperammonaemia 39.41 20.87 30 18173 6337 34932391
Vomiting 37.76 20.87 239 17964 247382 34691346
Protein urine present 37.69 20.87 27 18176 5201 34933527
Taste disorder 36.32 20.87 30 18173 7125 34931603
Pneumonitis 36.17 20.87 64 18139 33814 34904914
Neutropenia 35.05 20.87 19 18184 156759 34781969
Liver disorder 31.02 20.87 59 18144 32938 34905790
Pyrexia 30.35 20.87 285 17918 332728 34606000
Liver abscess 30.12 20.87 21 18182 3874 34934854
Nausea 29.55 20.87 288 17915 339620 34599108
Cerebral infarction 29.48 20.87 52 18151 27403 34911325
Hyperhidrosis 28.73 20.87 3 18200 75689 34863039
Fall 27.91 20.87 39 18164 202846 34735882
Renal impairment 27.79 20.87 110 18093 94403 34844325
Arterial haemorrhage 27.62 20.87 12 18191 870 34937858
Immune-mediated hypothyroidism 27.38 20.87 9 18194 300 34938428
Rhythm idioventricular 26.96 20.87 9 18194 315 34938413
Duodenal perforation 26.31 20.87 13 18190 1265 34937463
Tumour lysis syndrome 26.14 20.87 38 18165 17021 34921707
Colitis 25.55 20.87 59 18144 37691 34901037
Overdose 25.22 20.87 8 18195 91051 34847677
Protein induced by vitamin K absence or antagonist II increased 25.18 20.87 5 18198 18 34938710
Haemobilia 25.02 20.87 9 18194 395 34938333
Cholangitis acute 24.33 20.87 11 18192 877 34937851
Oesophageal fistula 23.65 20.87 8 18195 292 34938436
Tumour necrosis 23.29 20.87 12 18191 1276 34937452
Haemoptysis 22.91 20.87 54 18149 34952 34903776
Depression 22.83 20.87 11 18192 97087 34841641
Weight increased 22.71 20.87 10 18193 93023 34845705
Product dose omission issue 22.03 20.87 18 18185 119693 34819035
Asthenia 21.84 20.87 209 17994 245042 34693686
Hyperthyroidism 21.46 20.87 27 18176 10539 34928189
Intentional product use issue 21.15 20.87 3 18200 59813 34878915

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypertension 2018.38 22.43 1323 27113 329669 79386283
Malignant neoplasm progression 1954.31 22.43 955 27481 135035 79580917
Proteinuria 1481.73 22.43 522 27914 31980 79683972
Palmar-plantar erythrodysaesthesia syndrome 1173.98 22.43 442 27994 32692 79683260
Hypothyroidism 1064.87 22.43 469 27967 51923 79664029
Decreased appetite 1022.58 22.43 896 27540 341522 79374430
Hepatic encephalopathy 673.33 22.43 271 28165 23895 79692057
Platelet count decreased 482.03 22.43 460 27976 194204 79521748
Diarrhoea 426.41 22.43 953 27483 879536 78836416
Tumour haemorrhage 352.88 22.43 107 28329 4037 79711915
Immune-mediated hypothyroidism 294.77 22.43 64 28372 599 79715353
Malaise 266.18 22.43 557 27879 489312 79226640
Dysphonia 262.65 22.43 193 28243 56679 79659273
Hepatic function abnormal 252.71 22.43 209 28227 72898 79643054
Cholecystitis 230.79 22.43 126 28310 22086 79693866
Drug ineffective 213.86 22.43 61 28375 1080852 78635100
Pneumothorax 177.46 22.43 116 28320 28207 79687745
Blood thyroid stimulating hormone increased 174.79 22.43 80 28356 9628 79706324
Ascites 154.07 22.43 161 28275 75401 79640551
Thyroiditis 154.01 22.43 59 28377 4546 79711406
Blood pressure increased 148.01 22.43 268 28168 211092 79504860
Gastrointestinal perforation 140.92 22.43 60 28376 6077 79709875
Pyrexia 134.55 22.43 537 27899 678172 79037780
Adrenal insufficiency 127.67 22.43 95 28341 28392 79687560
Liver carcinoma ruptured 127.58 22.43 26 28410 173 79715779
Condition aggravated 124.55 22.43 16 28420 501108 79214844
Renal impairment 123.26 22.43 210 28226 157573 79558379
Hyperthyroidism 122.39 22.43 84 28352 22125 79693827
Stomatitis 119.52 22.43 199 28237 146558 79569394
Tracheal fistula 112.73 22.43 23 28413 154 79715798
Oesophageal varices haemorrhage 112.69 22.43 46 28390 4190 79711762
Toxicity to various agents 105.83 22.43 13 28423 421527 79294425
Cholecystitis acute 104.10 22.43 63 28373 13388 79702564
Nephrotic syndrome 101.36 22.43 58 28378 11116 79704836
Interstitial lung disease 96.11 22.43 156 28280 112444 79603508
Cardiac failure 95.42 22.43 186 28250 154656 79561296
Colitis 95.35 22.43 124 28312 73183 79642769
Dehydration 94.43 22.43 246 28190 247941 79468011
Blood bilirubin increased 92.39 22.43 116 28320 66116 79649836
Cholangitis 89.10 22.43 56 28380 12720 79703232
Immune-mediated hepatitis 88.12 22.43 37 28399 3619 79712333
Fistula 83.49 22.43 54 28382 12886 79703066
Tracheo-oesophageal fistula 79.93 22.43 22 28414 584 79715368
Drug interaction 73.68 22.43 28 28408 415155 79300797
Weight increased 73.52 22.43 7 28429 277379 79438573
Drug hypersensitivity 73.09 22.43 10 28426 298906 79417046
Off label use 72.04 22.43 134 28302 907081 78808871
Fatigue 71.44 22.43 570 27866 929157 78786795
Hypersensitivity 71.17 22.43 6 28430 262233 79453719
Posterior reversible encephalopathy syndrome 70.31 22.43 65 28371 26216 79689736
Hepatic failure 69.61 22.43 97 28339 61115 79654837
Pain 69.13 22.43 90 28346 703712 79012240
Arterial haemorrhage 65.36 22.43 27 28409 2534 79713418
Hyponatraemia 65.25 22.43 174 28262 177674 79538278
Immune-mediated myocarditis 62.02 22.43 21 28415 1132 79714820
Rheumatoid arthritis 61.80 22.43 3 28433 208467 79507485
Oesophageal fistula 61.74 22.43 17 28419 452 79715500
Product dose omission issue 61.18 22.43 8 28428 247529 79468423
Cerebral haemorrhage 60.57 22.43 88 28348 57585 79658367
Immune-mediated enterocolitis 60.34 22.43 31 28405 4799 79711153
Cerebral infarction 57.42 22.43 76 28360 45600 79670352
Sinusitis 57.36 22.43 3 28433 195498 79520454
Vomiting 56.44 22.43 418 28018 665410 79050542
Protein urine present 55.12 22.43 38 28398 10074 79705878
Hypertensive crisis 54.84 22.43 51 28385 20719 79695233
Fall 54.68 22.43 56 28380 487573 79228379
Ammonia increased 54.58 22.43 34 28402 7601 79708351
Infusion related reaction 53.30 22.43 9 28427 230228 79485724
Large intestine perforation 53.11 22.43 43 28393 14524 79701428
Myocarditis 52.88 22.43 51 28385 21682 79694270
Immune-mediated hepatic disorder 51.79 22.43 20 28416 1574 79714378
Pneumonitis 51.46 22.43 84 28352 60776 79655176
Intestinal perforation 50.34 22.43 45 28391 17381 79698571
Small intestinal perforation 49.57 22.43 24 28412 3273 79712679
Drug intolerance 48.18 22.43 17 28419 264102 79451850
Arthropathy 48.18 22.43 4 28432 177107 79538845
Joint swelling 47.10 22.43 22 28414 288624 79427328
Tumour lysis syndrome 46.95 22.43 50 28386 23889 79692063
Portal vein thrombosis 46.91 22.43 28 28408 5799 79710153
Swelling 46.91 22.43 10 28426 216701 79499251
Immune-mediated hyperthyroidism 46.47 22.43 11 28425 156 79715796
Treatment failure 45.97 22.43 4 28432 170482 79545470
Haemoptysis 45.60 22.43 76 28360 55923 79660029
Hyperammonaemia 43.11 22.43 34 28402 11059 79704893
Weight decreased 42.89 22.43 244 28192 354954 79360998
Nasopharyngitis 41.96 22.43 19 28417 253862 79462090
Depression 41.20 22.43 13 28423 216777 79499175
Overdose 40.90 22.43 8 28428 184198 79531754
Alopecia 40.33 22.43 16 28420 231339 79484613
Adrenocorticotropic hormone deficiency 40.15 22.43 16 28420 1369 79714583
Abdominal pain 39.65 22.43 256 28180 389313 79326639
Tumour rupture 39.20 22.43 12 28424 467 79715485
Pancreatitis 38.15 22.43 79 28357 68496 79647456
Epistaxis 37.77 22.43 106 28330 111409 79604543
Eastern Cooperative Oncology Group performance status worsened 37.11 22.43 17 28419 2048 79713904
Insomnia 36.55 22.43 21 28415 245149 79470803
Pulmonary embolism 35.50 22.43 138 28298 171516 79544436
Intentional product use issue 35.07 22.43 6 28430 152106 79563846
Amylase increased 34.48 22.43 30 28406 11179 79704773
Asthma 34.25 22.43 4 28432 135091 79580861
Musculoskeletal stiffness 34.14 22.43 10 28426 174998 79540954
Liver disorder 34.10 22.43 78 28358 72339 79643613
Primary adrenal insufficiency 33.89 22.43 9 28427 208 79715744
Hyperhidrosis 32.76 22.43 7 28429 151485 79564467
Paraesthesia 32.75 22.43 11 28425 176312 79539640
Immune-mediated dermatitis 32.74 22.43 11 28425 579 79715373
Injection site pain 32.54 22.43 4 28432 129834 79586118
Dizziness 32.47 22.43 89 28347 526352 79189600
Upper gastrointestinal haemorrhage 32.15 22.43 55 28381 41325 79674627
Urticaria 31.96 22.43 13 28423 185188 79530764
Contusion 31.91 22.43 7 28429 148769 79567183
Myelosuppression 31.89 22.43 54 28382 40242 79675710
Cancer pain 31.66 22.43 21 28415 5224 79710728
Duodenal perforation 30.23 22.43 15 28421 2157 79713795
Immune-mediated encephalitis 30.16 22.43 10 28426 505 79715447
Immune-mediated renal disorder 30.12 22.43 8 28428 185 79715767
Oxygen saturation decreased 29.95 22.43 5 28431 129042 79586910
Thrombocytopenia 29.89 22.43 179 28257 265080 79450872
Mucosal inflammation 29.78 22.43 76 28360 75504 79640448
Taste disorder 29.19 22.43 32 28404 15791 79700161
Aspartate aminotransferase increased 29.10 22.43 112 28324 138529 79577423
Discomfort 28.86 22.43 5 28431 125612 79590340
Cholangitis acute 28.75 22.43 13 28423 1519 79714433
Wheezing 28.26 22.43 4 28432 116660 79599292
Enterocolitis 27.91 22.43 30 28406 14482 79701470
Ileus 27.52 22.43 40 28396 26171 79689781
Anxiety 27.29 22.43 29 28407 248483 79467469
Pruritus 27.20 22.43 63 28373 394585 79321367
Nausea 26.72 22.43 484 27952 956712 78759240
Immune-mediated pancreatitis 26.65 22.43 8 28428 291 79715661
Malignant pleural effusion 26.58 22.43 16 28420 3364 79712588
Hypopituitarism 26.50 22.43 16 28420 3383 79712569
Oral pain 25.67 22.43 43 28393 31755 79684197
Oesophageal perforation 25.34 22.43 12 28424 1559 79714393
Tumour associated fever 24.75 22.43 10 28426 887 79715065
Female genital tract fistula 24.71 22.43 19 28417 5956 79709996
Rhythm idioventricular 24.52 22.43 9 28427 615 79715337
Liver abscess 24.49 22.43 19 28417 6035 79709917
Tracheal haemorrhage 24.01 22.43 9 28427 653 79715299
Gastric perforation 23.98 22.43 16 28420 4021 79711931
Peripheral swelling 23.87 22.43 37 28399 269580 79446372
Tumour pain 23.75 22.43 13 28423 2286 79713666
Gastrointestinal haemorrhage 23.73 22.43 110 28326 147609 79568343
Thyroid disorder 23.45 22.43 27 28409 14052 79701900
Lipase increased 23.20 22.43 29 28407 16437 79699515
Asthenia 22.97 22.43 281 28155 511408 79204544
Bronchitis 22.81 22.43 9 28427 130635 79585317
Peritonitis 22.75 22.43 38 28398 27998 79687954
Influenza 22.52 22.43 9 28427 129597 79586355

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EX08 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Other protein kinase inhibitors
FDA MoA N0000020000 Receptor Tyrosine Kinase Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:62434 ALK inhibitor
CHEBI has role CHEBI:63457 FGFR inhibitors
CHEBI has role CHEBI:65207 vascular endothelial growth factor receptor inhibitors
CHEBI has role CHEBI:71031 orphan drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Liver cell carcinoma indication 109841003 DOID:684
Endometrial carcinoma progressing after chemotherapy indication 254878006 DOID:2871
Follicular thyroid carcinoma indication 255028004 DOID:3962
Papillary thyroid carcinoma indication 255029007 DOID:3969
Hurthle cell carcinoma of thyroid indication 423158009 DOID:8161
Renal cell carcinoma indication 702391001 DOID:4450
Thymic carcinoma indication 722670005
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.09 acidic
pKa2 12.74 acidic
pKa3 13.02 acidic
pKa4 4.67 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL 9006256 July 27, 2027 METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL 9006256 July 27, 2027 METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL 11090386 Feb. 23, 2036 TREATMENT WITH LENVIMA BY ADMINISTERING LENVIMA AS A SUSPENSION
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL 11090386 Feb. 23, 2036 TREATMENT WITH LENVIMA BY ADMINISTERING LENVIMA AS A SUSPENSION

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL July 21, 2024 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL July 21, 2024 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Aug. 10, 2024 LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Aug. 10, 2024 LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Dec. 19, 2024 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Dec. 19, 2024 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Aug. 15, 2025 INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Aug. 15, 2025 INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase INHIBITOR Ki 8.82 CHEMBL DRUG LABEL
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR IC50 7 SCIENTIFIC LITERATURE DRUG LABEL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR IC50 7.66 SCIENTIFIC LITERATURE DRUG LABEL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR IC50 8.40 SCIENTIFIC LITERATURE DRUG LABEL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR IC50 8.28 SCIENTIFIC LITERATURE DRUG LABEL
Platelet-derived growth factor receptor alpha Kinase INHIBITOR IC50 7.29 SCIENTIFIC LITERATURE DRUG LABEL
Fibroblast growth factor receptor 1 Kinase INHIBITOR IC50 7.34 SCIENTIFIC LITERATURE DRUG LABEL
Mitogen-activated protein kinase 14 Kinase Kd 6.66 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 5.51 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 7.96 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 5.41 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 7.34 CHEMBL
Protein-tyrosine kinase 6 Kinase Kd 6.76 CHEMBL
MAP kinase-activated protein kinase 2 Kinase Kd 7.20 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 6.66 CHEMBL
Epidermal growth factor receptor Kinase INHIBITOR IC50 5.19 SCIENTIFIC LITERATURE
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 6.24 CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1 Kinase Kd 5.65 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 5.54 CHEMBL
Ferrochelatase, mitochondrial Enzyme Kd 5.55 CHEMBL
Receptor-interacting serine/threonine-protein kinase 3 Kinase Kd 6.50 CHEMBL
Mitogen-activated protein kinase kinase kinase 6 Kinase Kd 5.80 CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR IC50 7.41 SCIENTIFIC LITERATURE
Aurora kinase B Kinase Kd 5.75 CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme Kd 5.82 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 5.42 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 6.88 CHEMBL
Breakpoint cluster region protein Kinase Kd 5.39 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 6.10 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 6.25 CHEMBL

External reference:

IDSource
EE083865G2 UNII
D09919 KEGG_DRUG
4034239 VUID
N0000191429 NUI
857890-39-2 SECONDARY_CAS_RN
4034239 VANDF
C2986924 UMLSCUI
CHEBI:85994 CHEBI
LEV PDB_CHEM_ID
CHEMBL1289601 ChEMBL_ID
9823820 PUBCHEM_CID
DB09078 DRUGBANK_ID
CHEMBL2105704 ChEMBL_ID
9361 INN_ID
C531958 MESH_SUPPLEMENTAL_RECORD_UI
7426 IUPHAR_LIGAND_ID
1603296 RXNORM
232716 MMSL
294829 MMSL
294831 MMSL
30895 MMSL
d08346 MMSL
015899 NDDF
015900 NDDF
714108002 SNOMEDCT_US
714109005 SNOMEDCT_US
735068004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-704 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-704 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-704 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-704 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-708 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-708 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-708 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-708 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-710 CAPSULE 10 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-710 CAPSULE 10 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-710 CAPSULE 10 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-710 CAPSULE 10 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-712 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-712 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-712 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-712 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-720 CAPSULE 10 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-720 CAPSULE 10 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-720 CAPSULE 10 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-720 CAPSULE 10 mg ORAL NDA 32 sections